https://www.wsj.com/articles/fda-shuts-out-its-own-experts-in-authorizing-another-booster-covid-vaccine-pandemic-science-11649016728?mod=opinion_lead_pos7
The Food and Drug Administration last week authorized Americans 50 and over to get a fourth Covid vaccine dose. Some of the FDA’s own experts disagree with the decision, but the agency simply ignored them. It will convene its advisory committee this Wednesday to discuss future vaccine needs. That’s like having lawyers present arguments to a judge who’s already issued a verdict.
Eric Rubin, editor in chief of the New England Journal of Medicine, sits on the advisory committee. He told CNN last month that he hadn’t seen enough data to determine whether anyone needs a fourth dose whose immune system isn’t seriously deficient.
Another committee member, Cody Meissner, agrees. Dr. Meissner, chief of pediatric infectious diseases at Tufts Children’s Hospital, told me last week that the fourth dose is “an unanswered scientific question for people with a normal immune system.”
A third member of the committee, Paul Offit of the Children’s Hospital of Philadelphia, told the Atlantic that he advised his 20-something son to forgo the third shot, which the FDA recommends for everyone 12 and over.
At the crux of the broad opposition to second boosters is the recognition of B- and T-cells, which public-health officials have long ignored. They talk only about antibody levels, which tend to decline in the months after vaccination. B- and T-cells, activated by the primary vaccine series or an infection (and augmented by a single booster in older patients), are highly and durably effective at preventing serious illness from Covid. An additional vaccine dose induces a fleeting high in antibody levels, offering only mild and short-lived protection against infection.